当前位置: 首页 > 期刊 > 《新医学》 > 2023年第7期
编号:649682
LEAP-2和Ghrelin在代谢相关疾病的研究进展
http://www.100md.com 2023年7月27日 新医学 2023年第7期
生长激素,靶点,血浆
     李峰?霍宇琪?赵浩亮

    【摘要】 肝表达抗菌肽-2(LEAP-2)最近被发现是生长激素促分泌素受体1α(GHSR1α)的内源性配体,可拮抗胃促生长素(Ghrelin)的激活作用,后续发现还可以反向激动GHSR1α,降低GHSR1α的基础活性。这种拮抗关系,不仅在调节生长激素分泌方面发挥关键作用,还在调节食物摄入、肥胖、葡萄糖稳态等复杂功能方面发挥重要作用,并有望成为糖尿病、肥胖症、恶病质等代谢相关疾病诊断及治疗的新靶点。该文将结合Ghrelin来分析LEAP-2的作用,阐述其基本生物学功能和在相关疾病发生发展中的作用以及作为治疗靶点的潜力。

    【关键词】 肝表达抗菌肽-2;胃促生长素;GHSR1α信号转导通路;代谢相关疾病

    Research progress on LEAP-2 and Ghrelin in metabolism-related diseases Li Feng, Huo Yuqi, Zhao Haoliang. Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China

    Corresponding author, Zhao Haoliang, E-mail: 503777049@qq.com

    【Abstract】 Recently, liver-expressed antibacterial peptide 2 (LEAP-2) was found to be an endogenous ligand of growth hormone secretin receptor 1α(GHSR1α), which can antagonize the activation of Ghrelin. Subsequently, it was found that it can reverse the activation of GHSR1α and reduce the basic activity of GHSR1α. This antagonistic relationship not only plays a key role in regulating the secretion of growth hormone, but also plays an important role in regulating food intake ......

您现在查看是摘要页,全文长 15546 字符